Key Takeaways

  • Oakridge International issued 4,999,943 new fully paid ordinary shares on 30 June 2026 and lodged a Section 708A(6) cleansing notice on 2 July 2026, allowing the new stock to trade freely on the ASX.
  • The cleansing notice does not disclose the issue price, subscriber identities, or specific use of proceeds — these remain open questions for investors.
  • Oakridge's half-year accounts to 31 December 2025 showed a swing to profit but a sharp fall in cash to $151,219, alongside a going-concern note tied to its ability to keep raising capital.
  • The company is a thinly traded micro-cap with heavy insider control through Executive Chairman Con Unerkov's Montague Capital Pty Ltd.
  • Revenue has grown strongly over the past two reporting periods, driven by the JCT Healthcare nurse-call and patient-monitoring business, but cash runway and dilution remain key watch points.

The document at the centre of this story is a Section 708A(6) cleansing notice lodged with the ASX on 2 July 2026. A cleansing notice is a company's formal confirmation that it has complied with its continuous disclosure obligations and has no 'excluded information' withheld from the market. Once lodged, it removes the standard 12-month on-sale restriction that would otherwise apply to shares issued without a prospectus.

What the notice confirms is that Oakridge issued 4,999,943 fully paid ordinary shares, dated 30 June 2026. Company secretary Julie Edwards is named on the filing. Beyond that, the notice is procedural: it does not set out the placement price, the parties who subscribed for the shares, or the stated purpose of the capital raised.

Oakridge has a history of related-party placements — most notably a 2024 issue of 9,398,496 shares and 7,142,857 options to Montague Capital Pty Ltd, the vehicle controlled by Executive Chairman and CEO Con Unerkov, approved by shareholders at an Extraordinary General Meeting on 20 June 2024. That placement was priced at $0.0532 per share and raised $500,000, with an independent expert concluding the transaction was 'not fair but reasonable' to non-associated shareholders. Whether the June 2026 placement follows a similar related-party structure, involves new external investors, or was priced at a premium or discount to the market, is not something the cleansing notice itself reveals.

From Xped to JCT Healthcare: Oakridge's Business Today

Oakridge International, previously known as Xped Limited, operates as a healthcare technology provider headquartered in Adelaide, South Australia. Its principal operating business is JCT Healthcare Technology, which develops and distributes nurse-call hardware and software, including its NuCaMS platform, along with assistive and patient-monitoring technology for hospitals, aged care facilities, disability care providers, and supported independent living (SIL) accommodation.

According to company disclosures, JCT has been developing cloud-based integrations, including Microsoft Azure Single Sign-On support, aimed at making the platform suitable for larger enterprise healthcare deployments. Management has referenced installation and project activity across multiple major sites along with what it describes as a 'robust pipeline of quotes and tenders.'

The business is led by Executive Chairman and CEO Con Unerkov, who exercises effective control through Montague Capital Pty Ltd. Based on the most recent available shareholding data, Montague Capital's holding represents close to two-thirds of shares on issue. That concentration of ownership, and a board reported to lack an independent director, are structural features relevant to how investors weigh governance risk alongside the operational story.

Financial Position: Growth, a Return to Profit, and a Cash Squeeze

Oakridge's most recent full-year accounts, for the year ended 30 June 2025, showed revenue of $2,433,340, more than double the $1,177,029 recorded a year earlier. The company narrowed its loss after tax to $128,795, down sharply from a loss of $761,248 in the prior year. Cash on hand fell over the year to $468,939 from $961,575.

The half-year accounts to 31 December 2025 extended the revenue growth trend, with revenue of $1,789,640, up 61.9% on the prior corresponding half. The company swung to a statutory profit of $172,239 for the half — its first profitable half in the recent reporting history reviewed for this article.

That improvement came with a stark cash-flow caveat. Cash on hand fell to just $151,219 by 31 December 2025, down from $468,939 six months earlier, driven by an operating cash outflow of $480,634 for the half. The half-year report flagged going-concern dependency on continued profitability and the ability to raise further capital, and disclosed that Montague Capital Pty Ltd had provided a $215,000 interest-free advance to fund working capital.

Opportunities and Positive Factors

The clearest positive signal from Oakridge's recent disclosures is the trajectory of its underlying healthcare technology business. Revenue more than doubled in FY2025 and continued to grow at a robust rate into the first half of FY2026, while the company recorded its first half-year statutory profit in the periods reviewed. Management commentary points to installation and project activity across 'multiple major sites' and a healthy tender pipeline.

Product development around cloud integration, including Azure Single Sign-On support, points to an effort to position the NuCaMS platform for larger institutional deployments. Demand for nurse-call and patient-monitoring technology in Australian hospitals, aged care and disability care settings remains solid — a sector under ongoing regulatory pressure to modernise call and monitoring systems.

Risks and Uncertainties

Cash of $151,219 at the last reported balance date, alongside a going-concern note and an operating cash outflow that outpaced statutory profit, indicate the business remains financially fragile despite improving revenue. Reliance on an interest-free advance from the Executive Chairman's own investment vehicle, Montague Capital, highlights dependence on related-party support that may not always be available on the same terms.

Ownership is highly concentrated, and the board reportedly lacks an independent director — factors that concentrate decision-making power and reduce the checks typically expected of a listed board. The stock's very small market capitalisation and thin trading volumes mean meaningful positions can be difficult to buy or sell without materially moving the price. Finally, the specific terms of the June 2026 placement — price, subscribers, and intended use of funds — remain undisclosed, limiting how precisely investors can assess whether the raise was struck on favourable terms for existing shareholders.

Catalysts: What to Watch Next

The company's FY2026 annual results and Appendix 4E are expected around 21 August 2026, and should reveal the full-year cash position, revenue outcome, and commentary on the placement's purpose. Any further ASX filing specifying the placement price, participants, or intended use of the newly raised funds would sharpen the picture materially. Ongoing cash-flow reports will show whether the new capital has stabilised liquidity. Contract or tender wins from the JCT Healthcare business — particularly at large hospital, aged care, or SIL sites — would support the revenue growth narrative independently of financing activity. Investors may also watch for changes to board composition, given the flagged absence of independent directors.

A Balanced Conclusion

Oakridge International's confirmed news is straightforward: a nearly five-million-share placement completed on 30 June 2026, cleared for free trading by a cleansing notice lodged 2 July 2026. What is not yet confirmed — pricing, subscribers, and precise use of funds — matters more to how investors should interpret the event than the bare fact of the issue itself. Set alongside a business that has grown revenue substantially and recently turned profitable, but which entered this raise with a cash balance of roughly $151,000 and an explicit going-concern flag, the placement looks consistent with a company shoring up working capital — though that remains an inference from the surrounding financial disclosures rather than a stated fact. For a micro-cap this small, with concentrated insider ownership and thin liquidity, the coming annual result and any further disclosure on the placement's terms will do more to answer 'what comes next' than the cleansing notice alone.